GH1 and neoplasm: At baseline, our analyses demonstrate that depressive symptoms significantly predicted QoL measured by AcroQoL (p < 0.001) and SF-36 (p < 0.001) in acromegaly in a model including age, gender, disease duration, basal GH levels, tumor size, and possible treatment modalities and comorbidities as covariates.